1. 998TiPPamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China. (23rd October 2018) Authors: Wu, X; Wang, J; Zhou, Q; Gu, T; Zhang, K; Liang, J; Mu, S; Ge, R; Yang, H; Huang, V; Brachmann, R; Wang, L; Li, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗